Not yet recruiting
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
NCT07560358· Phase 3· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Zhijie Wang, MD
Recruiting
A Retrospective Real-World Study Based on RATIONALE-307
NCT07478809· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Wang Zhijie
Recruiting
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
NCT07438847· Phase 1· SHAOYAN LIU· Source
Contact: Ziren Kong, M.D.
Enrolling by invitation
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis
NCT07373951· Ming Yang· Source
Recruiting
CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
NCT07657403· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Ming Yang, M.D.
Recruiting
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
NCT07383246· Phase 3· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Ziren Kong, MD
Recruiting
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
NCT07014202· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Zhijie, MD
Recruiting
A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery
NCT07378683· Ming Yang· Source
Contact: Ming Yang, MD
Recruiting
A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer
NCT07026669· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Zhijie Wang, MD
Recruiting
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
NCT07057102· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Zhijie Wang, MD
Recruiting
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
NCT06277180· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Shaoyan Liu, M.D.
Recruiting
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
NCT05983107· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Fei Ma
Not yet recruiting
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892· Phase 3· Suzhou Puhe Pharmaceutical Technology Co., LTD· Source
Contact: Jie Wang, Doctor
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Xin Wang, doctor
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Xin Wang, Doctor
Recruiting
A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
NCT05603078· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Hao Jing, M.D.
Not yet recruiting
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
NCT04736589· Phase 3· Peking Union Medical College· Source
Contact: Fei Ma, MD
Recruiting
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source
Contact: Fengwei Tan, MD